Pangenomic Health Inc.
NARA
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -68.49% | -55.29% | -28.62% | 26.91% | 115.12% |
| Gross Profit | 68.49% | 55.29% | 28.62% | -26.91% | -115.12% |
| SG&A Expenses | -60.61% | -65.74% | -47.41% | -31.60% | -11.30% |
| Depreciation & Amortization | -6.67% | 3.37% | 5.75% | 7.06% | 12.50% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.48% | -66.67% | -49.51% | -26.47% | -5.28% |
| Operating Income | 65.48% | 66.67% | 49.51% | 26.47% | 5.28% |
| Income Before Tax | 70.43% | 70.27% | 82.57% | 75.38% | -120.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.43% | 70.27% | 82.57% | 75.38% | -120.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.43% | 70.27% | 82.57% | 75.38% | -120.39% |
| EBIT | 65.48% | 66.67% | 49.51% | 26.47% | 5.28% |
| EBITDA | 65.71% | 66.89% | 49.68% | 26.57% | 5.39% |
| EPS Basic | 88.21% | 86.94% | 87.42% | 83.47% | -9.09% |
| Normalized Basic EPS | 75.89% | 75.16% | 65.74% | 59.53% | 52.59% |
| EPS Diluted | 88.21% | 86.94% | 87.42% | 83.47% | -9.09% |
| Normalized Diluted EPS | 75.89% | 75.16% | 65.74% | 59.53% | 52.59% |
| Average Basic Shares Outstanding | 115.27% | 73.12% | 45.68% | 82.57% | 111.84% |
| Average Diluted Shares Outstanding | 115.27% | 73.12% | 45.68% | 82.57% | 111.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |